JP2005525397A5 - - Google Patents

Download PDF

Info

Publication number
JP2005525397A5
JP2005525397A5 JP2003583443A JP2003583443A JP2005525397A5 JP 2005525397 A5 JP2005525397 A5 JP 2005525397A5 JP 2003583443 A JP2003583443 A JP 2003583443A JP 2003583443 A JP2003583443 A JP 2003583443A JP 2005525397 A5 JP2005525397 A5 JP 2005525397A5
Authority
JP
Japan
Prior art keywords
tumor
therapeutic agent
agent according
solid tumor
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003583443A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005525397A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/NL2002/000231 external-priority patent/WO2003086424A1/en
Publication of JP2005525397A publication Critical patent/JP2005525397A/ja
Publication of JP2005525397A5 publication Critical patent/JP2005525397A5/ja
Pending legal-status Critical Current

Links

JP2003583443A 2002-04-10 2002-04-10 悪性腫瘍の処置のための亜ヒ酸塩を含む薬学的組成物 Pending JP2005525397A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2002/000231 WO2003086424A1 (en) 2002-04-10 2002-04-10 Pharmaceutical composition comprising arsenite for the treatment of malignancy

Publications (2)

Publication Number Publication Date
JP2005525397A JP2005525397A (ja) 2005-08-25
JP2005525397A5 true JP2005525397A5 (enExample) 2008-06-26

Family

ID=29244880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003583443A Pending JP2005525397A (ja) 2002-04-10 2002-04-10 悪性腫瘍の処置のための亜ヒ酸塩を含む薬学的組成物

Country Status (25)

Country Link
US (1) US20050106262A1 (enExample)
EP (2) EP1496918B1 (enExample)
JP (1) JP2005525397A (enExample)
CN (1) CN1298332C (enExample)
AP (1) AP2004003167A0 (enExample)
AU (2) AU2002253713B2 (enExample)
BG (1) BG66356B1 (enExample)
BR (1) BR0215689A (enExample)
CA (1) CA2481602C (enExample)
CY (1) CY1114422T1 (enExample)
DK (2) DK2042182T3 (enExample)
EC (1) ECSP045408A (enExample)
ES (2) ES2425418T3 (enExample)
FI (1) FI1496918T3 (enExample)
HU (1) HU230851B1 (enExample)
IL (2) IL164470A0 (enExample)
LT (1) LT1496918T (enExample)
MX (1) MXPA04009898A (enExample)
NO (1) NO335317B1 (enExample)
NZ (1) NZ536452A (enExample)
PT (2) PT2042182E (enExample)
RO (1) RO123269B1 (enExample)
TN (1) TNSN04198A1 (enExample)
UA (1) UA80426C2 (enExample)
WO (1) WO2003086424A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1789107B1 (en) * 2004-08-30 2009-05-27 Interstitial Therapeutics Medical stent provided with inhibitors of atp synthesis
EP1721615A1 (en) * 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
US20100249210A1 (en) * 2008-09-30 2010-09-30 Michael Bastiani Methods and compositions related to dlk-1 and the p38 mapk pathway in nerve regeneration
CN102060722B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种含砷化合物及其制备方法和用途
WO2011031890A2 (en) * 2009-09-10 2011-03-17 Kominox Usa, Inc. Cancer stem cell-targeted and drug resistant cancer therapy
JP2013505242A (ja) * 2009-09-18 2013-02-14 コミノックス・インコーポレイテッド 脳腫瘍を治療するための方法
CN101695501B (zh) * 2009-10-10 2013-08-14 广汉恒宇新材料有限公司 一种纳米尺寸亚砷酸的壳聚糖包载体及其制造方法
CA3094115A1 (en) 2018-03-22 2019-09-26 Komipharm International Australia Pty Ltd Pharmaceutical composition comprising meta arsenite and method of manufacture

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022336A1 (en) * 1994-02-18 1995-08-24 Tamara Vasilievna Vorobieva Agent having an immunomodulating effect and reducing disturbed functioning of the tissue cell propagation regulating system
ATE407683T1 (de) * 1997-10-15 2008-09-15 Polarx Biopharmaceuticals Inc Pharmazeutische zusammensetzungen enthaltend arsentrioxid zur behandlung von multiplen myelom
CN1119152C (zh) * 1998-08-02 2003-08-27 哈尔滨医科大学第一临床医学院 治疗消化系统肿瘤注射液及其应用

Similar Documents

Publication Publication Date Title
JP2008526765A5 (enExample)
DE602005026789D1 (de) Le
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
EP1535610A4 (en) THERAPEUTIC CANCER
JP2005525397A5 (enExample)
JP2007051159A5 (enExample)
NZ511938A (en) Use of AT-1 receptor antagonist or treating diseases associated with an increase of AT-1 receptor
TW200510419A (en) Cannabinoid receptor ligands and uses thereof
JP2004504381A5 (enExample)
RU2012140185A (ru) Ингибирование ангиогенеза
GB0121490D0 (en) Ciompounds
WO2005048950A3 (en) Tumor and infectious disease therapeutic compositions
NO20042035L (no) Forbedret anvendelse av antitumorforbindelse i kreftterapi
AU2003219555A8 (en) Depsipeptide for therapy of kidney cancer
RU2005129273A (ru) Противораковый агент, содержащий белок lk8 в качестве активного ингредиента
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
WO2006021412A3 (en) Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
NO20050428L (no) Arylkarbonylpiperaziner og heteroarylkarbonylpiperaziner og anvendelse derav for behandling av godartede og ondartede tumorsykdommer
EP1667716B8 (en) Cytotoxicity mediation of cells evidencing surface expression of cd44
RU2225710C2 (ru) Списулозиновые соединения, обладающие противоопухолевой активностью
EP2722060A3 (en) Guanylyl cyclase C ligands
FI1496918T3 (fi) Natriummeta-arseniitin käyttö kasvainten hoidossa
NO20055307D0 (no) Substituerte isokromanforbindelser for behandling av metabolske forstyrrelser, kreft og andre sykdommer
JP2007508316A5 (enExample)
SE0400708D0 (sv) New compounds and use thereof